Prescription Pharmaceuticals (Rx)
New mechanisms, regulated pathways
We bring emerging mechanisms of action into markets ready to adopt them, developed to full CTD dossier standard with the clinical substantiation the indication demands.
Pharmaceutical Innovation Platform · Latin America
Innovating to create value.
We turn frontier science into brands that lead their category — from concept through registration to the shelf, across every regulatory class in prescription and consumer health.
Lead the way™
The opportunity is not incremental. It is structural.
The Opportunity
Latin America rewards those who arrive with the right architecture.
The region is undergoing a structural shift in health consumption: an expanding self-care culture, a pharmacy-centric retail system with genuine category influence, demographic transition toward metabolic and longevity-driven demand, and regulatory frameworks converging toward international standards.
But an opportunity does not become category leadership on its own.
The Conversion Gap
Frontier science is abundant. The capability to convert it into a category is not.
Between a promising molecule and a brand leading its category at mass-consumption scale sits a sequence that very few organisations hold end to end. Each link is specialised. Held separately, they accumulate cost and time. Held together, they compress both.
Proprietary development end-to-end
Science that becomes an owned asset, built from its origin to scale, not a licensed input.
Classification and claim strategy
The regulatory route determines the commercial ceiling before a single filing is made.
Market-by-market end-to-end execution
Every authority in the region applies its own standard of evidence, dossier and review rhythm.
Architecture for mass consumption
Designed from the first formulation for the scale of the category it intends to lead.
XANUM exists to hold that sequence end to end.
The Gateway
The gateway to the best innovation in every category we enter.
We do not select categories in order to occupy them. We enter where the science is moving, and we bring the frontier with us — engineered from the first formulation for mass-consumption scale.
Consumer Healthcare (OTC)
Pharmaceutical substance at everyday scale
The highest-volume categories in the region. We enter them with pharmaceutical-grade substantiation and the claim architecture that unlocks mass adoption.
Bioactive Natural Medicines
Botanical tradition, pharmaceutical rigour
The category legitimising fastest in the region. We bring characterised actives, standardised extracts and validated delivery to a space that has historically lacked them.
Nutritional Supplements
From commodity to branded platform
We build nutraceutical platforms with substantiated claims and formats designed around real consumption occasions — the shift from undifferentiated supplement to category-defining brand.
Substance-Based Medical Devices
A classification frontier few navigate
Devices acting by physical or physicochemical mechanism — a pathway that unlocks claims unavailable elsewhere, and among the most demanding to document. We navigate it.
Dermocosmetics & Nutricosmetics
Where clinical efficacy meets the beauty economy
Dermatological substantiation delivered with consumer-grade sensory experience — the convergence of two of the largest consumer categories in the region.
Advanced Modality
Peptide Therapeutics
The modality reshaping metabolic health
Synthetic peptide assets for metabolic and specialty indications, developed exclusively through regulated pathways: GMP-qualified API sourcing and supplier qualification, full characterisation and impurity profiling, and a stability and delivery strategy appropriate to the modality.
Forms we turn into advantage
Every format is chosen as a strategic variable: the way a product is used becomes a reason for preference, differentiation and scale.
Hard capsules
Dosing versatility
Two-piece capsules for powders, granules and microgranules.
Flexible dosing design
Compatible with modified release
Stability for sensitive ingredients
The discipline behind the portfolio
Three decisions that turn every asset into a category position, not just another product.
Claim architecture
We select the regulatory class that unlocks the strongest defensible claim for each asset rather than accepting the default pathway, so that the product reaches the market with the strongest argument available.
Category laddering
Assets are tiered and sequenced so the portfolio expands the category instead of competing with itself, so that every launch adds volume rather than dividing it.
Defensible differentiation
Every concept is built to hold proprietary ground across formulation, method, delivery system and brand architecture, so that the position won is not copied in the next cycle.
We do not enter a category to participate in it. We enter to decide where it goes next.
Being the gateway demands a discipline, not a service.
Innovation Leadership
Innovation is our operating standard, not a department.
Our Innovation Catalyst philosophy and Forward Solutions methodology exist for one purpose: to convert an opportunity into a brand that leads its category — a distinctive concept with high intellectual property content, supported by rigorous scientific evidence, high-quality production and a communication strategy built to lead.
- 01
Explore opportunities
Identify high-impact space where science, pathway and demand converge.
- 02
Develop added value
A distinctive concept with defensible intellectual property.
- 03
Technical dossier and evidence
Scientific substantiation and proprietary studies where required.
- 04
Registration and production
Health authorisation and high-standard manufacturing.
- 05
Market strategy
Positioning and communication designed to lead the category.
But science alone has never written a prescription.
Commercial Architecture
A registration is permission. Category leadership is built after it.
The distance between an approved asset and a brand that leads its category is covered by disciplines that rarely travel together: brand and packaging design of international standard, market strategy delivered ready to execute, and a field force capable of holding a scientific conversation with a physician. We work alongside our partners across all three.
Design that earns its place on the shelf
Brand architecture, naming, visual identity and structural packaging developed to international standard: the assets that carry a scientific proposition into a purchase decision. Every design decision is made against the category the asset intends to lead, never against a template.
Strategy delivered ready to execute
Positioning, claim hierarchy, launch sequencing, channel and trade architecture, and the complete communication system — developed together with our partners and handed over finished. Not a deck of recommendations: an executable plan with the materials that make it work.
The medical visit is where the science lands
In prescription and pharmacy channels, a brand is decided in the minutes a representative spends with a healthcare professional. We train those teams virtually and continuously: in the science behind the molecule, the clinical conversation it supports, and the evidence that answers a specialist's objection. The training is delivered by the same team that built the dossier.
The enablement system
Virtual academy
Continuous programmes delivered remotely across every market, in Spanish and Portuguese.
Scientific narrative
Mechanism, evidence and clinical argument, structured for a real consultation.
Objection handling
Prepared responses to the questions a specialist actually asks.
Field materials
Detail aids, scientific summaries and digital tools built from the source dossier.
We do not hand our partners a product. We hand them a brand their teams know how to defend.
Evidence earns the right to scale. Scale is where value is created.
The Partnership Equation
Originated innovation. Shared scale.
We originate the science and turn it into assets designed to scale. Our partners contribute the commercial reach that turns a category-defining asset into a category-defining brand.
Innovation of exclusive origin
We originate the science behind every asset: formulations, methods, delivery systems and brand architecture. For our partners, that means entering a category on exclusive, defensible ground — not undifferentiated space — with rights defined together.
Protection defined line by line
Patent filing, trade secret, regulatory exclusivity or brand architecture — the route is selected according to where the defensible ground sits for each line, so that exclusivity outlasts the first year of sales.
Engineered for mass consumption
Every asset is built from the first formulation for the scale of the category it intends to lead, so that growth never requires redesigning the product halfway through.
Reach as the multiplier
Your commercial infrastructure converts a proprietary asset into regional or global share. Our science, your scale — that is the equation.
Models of Collaboration
Four ways to build value together.
Bring your asset into Latin America
We take responsibility for classification strategy, dossier, registration, production and market entry across the region.
Take our platforms into your markets
Developed concepts and proprietary formulations, ready to be adapted and launched under your commercial reach.
Build new assets together
Joint development programmes with intellectual property structured to reflect each party's contribution.
End-to-end partnership
From concept to point of sale, under a single accountable counterpart in every market.
We can enter at any stage of the development cycle — beginning, middle or final.
Proof of Execution
Programmes already executed, described without identifying anyone.
Three real programmes, presented by regulatory class, challenge and outcome.
Challenge
Build a probiotic spore portfolio with genuine added value across multiple technology tiers.
Outcome
A tiered platform spanning several formulations, each occupying distinct commercial territory within the same category.
Challenge
Develop a patented pharmaceutical asset for an occasion the category had never addressed with regulated science.
Outcome
A protected formulation supported by its own technical dossier, launched into a category created rather than entered.
Challenge
Bring a phytotherapeutic portfolio to market with delivery technology and scientific substantiation the category had lacked.
Outcome
A range built on characterised actives and validated delivery, substantiated for the claims it carries.
Programmes are described without identifying brands or partners. Full detail available under confidentiality.
Governance & Assurance
Delegating execution should never mean surrendering control.
Partnering with a regional platform raises a legitimate question about standards, oversight and exposure. We answer it before it is asked.
Quality systems that meet your standard
Manufacturing executed to GMP standard with documented supplier qualification, specification control and full batch traceability. Your quality bar becomes the operating bar.
Defined decision rights
Governance structure agreed at the outset: what is decided jointly, what is decided locally, and what escalates. No ambiguity when it matters.
Full visibility, market by market
Regulatory status, filing progress and post-authorisation obligations reported transparently across every market in the programme.
Reputational protection as a discipline
Pharmacovigilance, compliance and audit readiness are maintained continuously — not assembled when an inspection is announced.
The reputation you place in our hands is protected as if it were our own — because in this region, it is.
Executed market by market, across a region that consumes at scale.
Regional Reach
A region that consumes at scale.
Not a single market and not a pilot, but a region whose pharmacy channel moves consumer-goods volume with pharmaceutical credibility — with the infrastructure and market-by-market knowledge already in place.
+0
markets with regional presence
+0
years of trajectory in the sector
One platform, the entire region
- Mexico
- Central America
- Caribbean
- Colombia
- Ecuador
- Peru
- Andean Region
- Southern Cone
- Brazil
Nine regional fronts covering more than eleven markets with an active health registration, product in market or live commercial agreement.
Corporate Standing
A corporation built for global scale.
We operate as a corporation legally constituted in three strategic jurisdictions — the institutional base for collaborating with any company in the world.
United States
Constituted entity — vehicle for the United States market.
Latin America
Parent operation and base for development, production and regional commercialisation.
Spain
Constituted presence — gateway to the European market.
The Invitation
Let’s create value together.
Innovation is not simply doing something different — it is bringing people what they are genuinely looking for. If your company intends to win Latin America, let’s build it together.
Start the conversation
Contact us
Let’s talk about your next category.
Tell us briefly about your interest and the XANUM team will reply directly and in confidence.
All communication is confidential.